GX 12

Drug Profile

GX 12

Alternative Names: GX-12; HIV DNA vaccine - Dong-A Pharmaceutical; Naked DNA vaccine for HIV-1 infections - Dong-A

Latest Information Update: 27 Jul 2010

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical; Genexine
  • Developer Dong-A Pharmaceutical
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 01 Aug 2007 Phase-I clinical trials in HIV-1 infections in South Korea (IV)
  • 01 Aug 2007 Phase-I clinical trials in HIV-1 infections in South Korea (IM)
  • 30 Jun 2003 Preclinical trials in HIV infections in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top